Thank you for the information. I am in the regen med space, but not yet in NBS, though it seems very compelling. It's hard to put the story together unless one has been watching the stock closely for years, which I haven't been.
NBS recently announced the first patient entered into their phase 3 melanoma trial. Is it correct that the original approval for this trial was given to California Stem Cell, which was later acquired by NBS? The approval for the trial was December 3, 2013, can anyone explain why it took so long to begin the trial, which had fast track status as well? Was it just the fact that NBS acquired CSC that slowed things down? TIA